Home / Events / Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies

Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies

Prof Enriqueta Felip

Head of the Thoracic and Head and Neck Cancer Unit, Oncology Department of Vall d’Hebron Hospital, Barcelona, Spain

Prof Haiquan Chen

Chairman, Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, China

You are viewing an International Congress run by ATORG, The Hong Kong Cancer Therapy Society, and Roche and provided to international HCPs from around the world. Please note that prescribing information provided here may vary depending on local approval in each country. For purposes of Lung Cancer Forum, best efforts were undertaken by ATORG, The Hong Kong Cancer Therapy Society, and Roche to ensure compliance with the applicable law and regulations, however, you should review your local prescribing information and consult directly the local affiliate of the relevant Company to address any questions.

Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies

Prof Enriqueta Felip

Prof Haiquan Chen

Be the first to receive updates, event opportunities, and thought leadership insights.